Who Paid My Doc
Uzma Qureshi
Nurse Practitioner Los Angeles, CA Nurse Practitioner
NPI 1588858674 CMS profile 11116321
1520 San Pablo St, Suite 4300, Los Angeles, CA 90033
General payments
$5,683
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Uzma Qureshi of Los Angeles, CA is reported in the CMS Open Payments database as having received $5,683 across 84 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,151 | 12 | |
| 2024 | General | $1,343 | 18 | |
| 2023 | General | $1,772 | 26 | |
| 2022 | General | $420 | 5 | |
| 2021 | General | $997 | 23 |
Beside peers
- Uzma Qureshi
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Uzma Qureshi were reported at $1,151. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Uzma Qureshi | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $997 | $135 | $40–$426 | $132 |
| 2022 | $420 | $152 | $48–$470 | $149 |
| 2023 | $1,772 | $166 | $54–$529 | $160 |
| 2024 | $1,343 | $173 | $55–$556 | $164 |
| 2025 | $1,151 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
384
Drug cost
$133,779
Branded share of claims
16.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Sandostatin Lar Depot Octreotide Acetate,mi-Spheres | Brand | 20 | $83,899 | |
| Entresto Sacubitril/Valsartan | Brand | 33 | $31,596 | |
| Sildenafil Citrate | Generic | 24 | $8,726 | |
| Farxiga Dapagliflozin Propanediol | Brand | 12 | $5,760 | |
| Amiodarone Hcl | Generic | 17 | $1,117 | |
| Warfarin Sodium | Generic | 71 | $805 | |
| Bumetanide | Generic | 23 | $361 | |
| Hydralazine Hcl | Generic | 15 | $356 | |
| Amlodipine Besylate | Generic | 35 | $266 | |
| Atorvastatin Calcium | Generic | 34 | $246 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
84 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in California
Related records
Nurse Practitioner in California
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.